{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:19:52Z","timestamp":1790277592298,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005612.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000}}],"reference-count":51,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005612.pub5","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:23:32Z","timestamp":1648560212000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pregabalin add-on for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2022","author":[{"given":"Mariangela","family":"Panebianco","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics; Institute of Systems, Molecular and Integrative Biology, University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bresnahan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics; Institute of Systems, Molecular and Integrative Biology, University of Liverpool; Liverpool UK"},{"name":"Liverpool Reviews and Implementation Group, Department of Health Data Science; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics; Institute of Systems, Molecular and Integrative Biology, University of Liverpool; Liverpool UK"},{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD005612.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/0883073818821035","article-title":"Pregabalin as adjunctive treatment for focal onset seizures in pediatric patients: a randomized controlled trial","volume":"34","author":"Antinew","year":"2019","journal-title":"Journal of Child Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005612.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures","volume":"45","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD005612.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eplepsyres.2010.05.008","article-title":"A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures","volume":"91","author":"Baulac","year":"2010","journal-title":"Epilepsy Research"},{"issue":"3","key":"10.1002\/14651858.CD005612.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/01.WNL.0000150932.48688.BE","article-title":"Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy","volume":"64","author":"Beydoun","year":"2005","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD005612.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","article-title":"Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study","volume":"46","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"issue":"10","key":"10.1002\/14651858.CD005612.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.WNL.0000068024.20285.65","article-title":"Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures","volume":"60","author":"French","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD005612.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/epi.12690","article-title":"Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial","volume":"55","author":"French","year":"2014","journal-title":"Epilepsia"},{"issue":"12","key":"10.1002\/14651858.CD005612.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/WNL.0000000000003118","article-title":"Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes","volume":"87","author":"French","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD005612.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2008.01954.x","article-title":"Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial","volume":"50","author":"Lee","year":"2009","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD005612.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/epi.16466","article-title":"Pregabalin adjunctive therapy for focal onset seizures in children 1 month to < 4 years of age: a double-blind, placebo-controlled, video-electroencephalographic trial","volume":"61","author":"Mann","year":"2020","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD005612.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/epi.12679","article-title":"Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial","volume":"55","author":"Zaccara","year":"2014","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD005612.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.25641","article-title":"Therapeutic drug monitoring of newer antiepileptic drugs: a randomized trial for dosage adjustment","volume":"87","author":"Aicua-Rapun","year":"2020","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"106433","DOI":"10.1016\/j.eplepsyres.2020.106433","article-title":"Network meta-analysis of antiepileptic drugs in focal drug-resistant epilepsy","volume":"167","author":"Hu","year":"2020","journal-title":"Epilepsy Research"},{"issue":"12","key":"10.1002\/14651858.CD005612.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/14737175.2019.1681265","article-title":"Immediate and controlled-release pregabalin for the treatment of epilepsy","volume":"19","author":"Morano","year":"2019","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"106218","DOI":"10.1016\/j.eplepsyres.2019.106218","article-title":"Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: pooled analysis of data from randomized clinical trials","volume":"158","author":"Moseley","year":"2019","journal-title":"Epilepsy Research"},{"issue":"1","key":"10.1002\/14651858.CD005612.pub5-BIB0016|cit16","first-page":"49","article-title":"Comparative efficacy of zonisamide and pregabalin as an adjunctive therapy in children with refractory epilepsy","volume":"9","author":"Taghdiri","year":"2015","journal-title":"Iranian Journal of Child Neurology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005612.pub5-BIB0017|cit17","first-page":"172, Abstract n","article-title":"Comparative dosage adjustment of levetiracetam and pregabalin as adjunctive therapy for refractory partial epilepsy with polytherapy: a prospective observational randomized study","volume":"47","author":"Russi","year":"2006","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD005612.pub5-BIB0018|cit18","first-page":"69","article-title":"Open label, randomised, cross-over trial in epilepsy patients with cryptogenic focal, refractory epilepsy, comparing levetiracetam and pregabalin as add-on therapy","volume":"48","author":"Tata","year":"2007","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD005612.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"issue":"10","key":"10.1002\/14651858.CD005612.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clinical Pharmacokinetics"},{"issue":"9","key":"10.1002\/14651858.CD005612.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.seizure.2009.07.005","article-title":"Retention rate of pregabalin in drug-resistant epilepsy: 1-year follow-up, single-centre observation in 105 consecutive, adult patients","volume":"18","author":"Brandt","year":"2009","journal-title":"Seizure"},{"issue":"9","key":"10.1002\/14651858.CD005612.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1528-1167.2005.19204.x","article-title":"Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy","volume":"46","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"issue":"8968","key":"10.1002\/14651858.CD005612.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the National General Practice Study of Epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2377-10-104","article-title":"Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships","volume":"10","author":"Delahoy","year":"2010","journal-title":"BMC Neurology"},{"issue":"2","key":"10.1002\/14651858.CD005612.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0028-3908(01)00172-1","article-title":"Inhibition of neuronal (Ca2+) influx by gabapentin and pregabalin in the human neocortex","volume":"42","author":"Fink","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0026|cit26","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"12","key":"10.1002\/14651858.CD005612.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1586\/ern.09.114","article-title":"Management of the patient with medically refractory epilepsy","volume":"9","author":"Granata","year":"2009","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"2","key":"10.1002\/14651858.CD005612.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.seizure.2005.11.005","article-title":"Pregabalin: a new antiepileptic drug for refractory epilepsy","volume":"15","author":"Hamandi","year":"2006","journal-title":"Seizure"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0029|cit29","volume-title":"Epilepsy: Frequency, Causes and Consequences","author":"Hauser","year":"1990"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0030|cit30","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"4","key":"10.1002\/14651858.CD005612.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1528-1157.1989.tb05317.x","article-title":"Guidelines for clinical evaluation of antiepileptic drugs","volume":"30","author":"Commission on Antiepileptic Drugs of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0032|cit32","unstructured":"Comparison of the effect of zonisamide and pregabalin as adjunctive therapy in control of interactable epilepsy in children en.irct.ir\/trial\/11012"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0034|cit34","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD005612.pub5-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002896.pub2","article-title":"Vagus nerve stimulation for partial seizures","author":"Panebianco","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD005612.pub5-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001909.pub2","article-title":"Lamotrigine add-on for drug-resistant partial epilepsy","author":"Ramaratnam","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0037|cit37","unstructured":"Version 5.4, The Cochrane Collaboration, 2020 Review Manager (RevMan)"},{"issue":"6","key":"10.1002\/14651858.CD005612.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2147\/NDT.S4716","article-title":"Pregabalin for the management of partial epilepsy","volume":"4","author":"Ryvlin","year":"2008","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"g6501","DOI":"10.1136\/bmj.g6501","article-title":"Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews","volume":"349","author":"Saini","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD005612.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0041|cit41","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Grade Working Group Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD005612.pub5-BIB0042|cit42","unstructured":"Stata StataCorp 2015"},{"issue":"24","key":"10.1002\/14651858.CD005612.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/1097-0258(20001230)19:24<3417::AID-SIM614>3.0.CO;2-L","article-title":"A multilevel model framework for meta-analysis of clinical trials with binary outcomes","volume":"19","author":"Turner","year":"2000","journal-title":"Statistics in Medicine"},{"issue":"Spec No. 1","key":"10.1002\/14651858.CD005612.pub5-BIB0044|cit44","first-page":"5S376","article-title":"Quality-of-life scales for patients with drug-resistant partial epilepsy","volume":"160","author":"Villeneuve","year":"2004","journal-title":"Revue Neurologique"},{"issue":"7","key":"10.1002\/14651858.CD005612.pub5-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010541.pub2","article-title":"Surgery for epilepsy","author":"West","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD005612.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00228-012-1213-x","article-title":"The adverse event profile of pregabalin across different disorders: a meta-analysis","volume":"68","author":"Zaccara","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD005612.pub5-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009429.pub2","article-title":"Pregabalin monotherapy for epilepsy","author":"Zhou","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005612.pub5-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005612","article-title":"Pregabalin add-on for drug-resistant partial epilepsy","author":"Lozsadi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD005612.pub5-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005612.pub4","article-title":"Pregabalin add-on for drug-resistant focal epilepsy","author":"Panebianco","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005612.pub5-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005612.pub2","article-title":"Pregabalin add-on for drug-resistant partial epilepsy","author":"Pulman","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD005612.pub5-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005612.pub3","article-title":"Pregabalin add-on for drug-resistant partial epilepsy","author":"Pulman","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T03:03:30Z","timestamp":1679972610000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005612.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005612.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}